Alexander V. Stolbovoy , Nidal Islim , Ilya E. Loiko , Darya P. Zvereva , Svetlana S. Sobina
Abstract
The actuality of perfection of patient’s management with cervix cancer explains by one of the most value of this disease in women with peak of morbidity nearly 25–44 years and with continuously high mortality. Radiotherapy is the base of treatment, which in this case has peculiarity practically no inherent in other cancers. Russian and foreign oncologists saved up great experience in the treatment of patients with cervix uteri which was summarized in scientific literature, official standards and practical guidelines. There were a lot of news and additions on a background of impetuous progress in the radiotherapy oneself and at one time with progress in surgery and chemotherapy. Reasoning from needs of practical medicine we have to analyze it from nowadays positions. It is interesting to know what is official standards and scientific news and their interaction.
Keywords: cervix uteri, combined radiotherapy, brachytherapy, standards of the treatment.
About the Author
Alexander V. Stolbovoy 1 , Nidal Islim 1 , Ilya E. Loiko 2 , Darya P. Zvereva 2 , Svetlana S. Sobina 11 Russian Medical Academy of Continuous Professional Education, Moscow, Russia
2 European Medical Center, Moscow, Russia
References
1. Состояние онкологической помощи населению России в 2022 году. Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Московский НИОИ им. П.А. Герцена, Российский Центр информационных технологий и эпидемиологических исследований в области онкологии. М., 2023. The state of cancer care for the Russian population in 2022. Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Herzen Moscow Research Institute, Russian Center for Information Technology and Epidemiological Research in the Field of Oncology, Moscow, 2023 (in Russian).
2. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. Московский НИОИ им. П.А. Герцена, Российский Центр информационных технологий и эпидемиологических исследований в области онкологии. М., 2020. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Ed. A.D. Kaprin, V.V. Starinsky, A.O. Shakhzadova. Herzen Moscow Research Institute, Russian Center for Information Technology and Epidemiological Research in the Field of Oncology. Moscow, 2020 (in Russian).
3. Мерабишвили В.М. Состояние онкологической помощи в России: эпидемиология и выживаемость больных злокачественными заболеваниями (однолетняя и пятилетняя) по всем локализациям опухолей. Материалы XXVII онкологического конгресса. Злокачественные опухоли. 2023;13(3s1):89. Merabishvili V.M. The state of oncological care in Russia: epidemiology and survival of patients with malignant diseases (one-year and five-year) in all tumor localities. Materials of the XXVII Cancer Congress. Malignant tumors. 2023;13(3c1):89 (in Russian).
4. Bhatla N, Berek JS, Fredes MC et al. Revised FIGO Staging for carcinoma of the cervix uteri. Int J Gynecol Obstet. 2019;145:129-135.
5. Рак шейки матки. Клинические рекомендации Минздрава России. ID: 537. Рубрикатор клинических рекомендаций. М., 2020. URL: https://cr.minzdrav.gov.ru/recomend/537_1 (дата обращения 26.11.2023). Cervical cancer. Clinical recommendations of the Ministry of Health of the Russian Federation. ID: 537. Rubricator of clinical recommendations. Moscow, 2020. URL: https://cr.minzdrav.gov.ru/recomend/ 537_1 (accessed 11/26/2023) (in Russian).
6. Бойко А.В., Демидова Л.В., Дунаева Е.А., Дубовецкая О.В. Рак шейки матки. В кн.: Стандарты лучевой терапии. Под ред.
А.Д. Каприна, А.А. Костина, Е.В. Хмелевского. М.: ГЭОТАР-Медиа, 2019. С. 221-227. Boyko A.V., Demidova L.V., Dunaeva E.A., Dubovitskaya O.V. Cervical cancer. In: Standards of radiation therapy. Ed. A.D. Kaprin, A.A. Kostin, E.V. Khmelevsky. Moscow, GEOTAR-Media, 2019. P. 221-227. (in Russian).
7. NCCN Guidelines Version 1.2024 Cervical Cancer. NCCN Guidelines Version 1.2022 Cervical Cancer. URL: https://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf (date of access 25.11.2023).
8. Pötter R, Haie-Meder C, van Limbergen E et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy – 3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiother Oncol. 2006;78(1):67-77.
9. Hellebust T, Kristis C, Berger D et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. Radiotherapy and Oncology. 2010;96(2):153-60.
10. Dimopouls J, Petrow P, Tanderup K et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. Radiotherapy Oncology. 2012;103(1):113-22.
11. ICRU Report No. 89. Prescribing, recording, and reporting brachytherapy for cancer of the cervix. Journal of the ICRU. 2013;13(1-2):274.
12. Damast S, Fields E, Kidd E et al. Reports From Four International Clinical Trials for Cancers of the Cervix, Uterus and Vulva, and a New Guideline for Cervical Cancer. Int J Radiat Oncol Biol Phys. 2021;111(2):299-306. DOI: 10.1016/j.ijrobp.2021.05.002
13. Viswanathan A, Creutzberg C, Craighead P et al. International brachytherapy practice patterns: a survey of the Gynecologic Cancer Intergroup (GCIG). Int J Radiation Oncol, Biology, Physics. 2012;82(1):250-5. DOI: 10.1016/j.ijrobp.2010.10.030
14. Toita T, Ohno T, Kaneyasu Y et al. JCOG Radiation Therapy Study Group. A consensus-based guideline defining clinical target volume for primary disease in external beam radiotherapy for intact uterine cervical cancer. Jpn J Clin Oncol. 2011;41(9):1119-26. DOI: 10.1093/jjco/hyr096
15. Benedetti-Panici P, Greggi S, Colombo A et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. Journal of Clinical Oncology. 2002;20(1):179-88. DOI: 10.1200/jco.2002.20.1.179
16. Datta N, Stutz E, Gomez S, Bodis S. Efficacy and safety evaluation of the various therapeutic options in locally advanced cervix cancer: A systematic review and network metaanalysis of randomized clinical trials. Int J Radiation Oncol Biology Physics. 2019;103(2):411-37. DOI: 10.1016/j.ijrobp.2018.09.037
17. Хохлова С.В., Коломиец Л.А, Кравец О.А. и др. Практические рекомендации по лекарственому лечению рака шейки матки. Злокачественные опухоли: Практические рекомендации RUSSCO. 2021;11(3s2):206. Khokhlova S.V., Kolomiets L.A., Kravets O.A. et al. Practical recommendations for the drug treatment of cervical cancer. Malignant tumors: Practical recommendations RUSSCO. 2021;11(3s2):206. (in Russian).
18. Barraclough LR. External beam boost for cancer of the cervix uteri when intracavitary therapy cannot be performed. Int J Radiation Oncology Biol Phys. 2008;71(3):772-8. DOI: 10.1016/j.ijrobp.2007.10.066
19. Castro J, Issa P, Fletcher G. Carcinoma of the cervix treated by external irradiation alone. Radiology. 1970;95(1):163-6. DOI: 10.1148/95.1.163. PMID: 4984677
20. Справочник лучевого терапевта. Под общ. ред. А.Д. Каприна,
Ю.С. Мардынского, И.А. Гулидова; ФГБУ НМИЦ радиологии Минздрава России; Российская ассоциация терапевтических радиационных онкологов. М.: Молодая гвардия, 2020. The radiotherapist’s Handbook. Ed. A.D. Kaplin, Yu.S. Mardynsky,
I.A. Gulidov; National Medical Research Radiological Center of the Ministry of Health of the Russian Federation; Russian Association of Therapeutic Radiation Oncologists. Moscow: Molodaya Gvardiya, 2020 (in Russian).
21. IARC. World cancer report. Wild C, Wiederpass E, Stewart B et al. Lyon: WHO, 2020. P. 30–31.
22. Кравец О.А. Лучевая терапия местнораспространенного рака шейки матки (оптимизация лечения, факторы прогноза). Автореф. дисс… д-ра мед. наук: 14.0012, 14.00.13. Кравец Ольга Александровна. М., 2010. Kravets O.A. Radiation therapy of locally advanced cervical cancer (optimization of treatment, prognostic factors). The author’s abstract. diss... Doctor of Medical Sciences: 14.0012, 14.00.13. Kravets Olga Alexandrovna. Moscow, 2010 (in Russian).
23. Bandyopadhyay A, Mukherjee U, Ghosh S et al. Pattern of failure with locally advanced cervical cancer – a retrospective audit and analysis of contributory factors. Asian Pac Cancer Prev. 2018;19(1):73-9.
24. Coia L, Won M, Lanciano R et al. the patterns of care outcome study for cancer of uterine cervix. Results of second national practice survey. Cancer. 1990;66(12):2451-6.
25. Perez C, Camel H, Kuske R et al. Radiation therapy alone in the treatment of carcinoma of the uterine cervix: A 20-year experience. Gynecol Oncol. 1986;23(2):127-40.
26. Landoni F, Maneo A, Colombo A et al. Randomised stady of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet. 1997;350(9077):535-40.
27. Cengiz M, Gurdalli S, Genc M et al. Comment on «Correlation between the treated volume, the GTV and the CTV at the time of brachytherapy and histopathologic finding in 33 patients with operable cervix carcinoma». Radiother Oncol. 2005;75:367-8.
28. Cengiz M, Gurdalli S, Selek U et al. Effect of bladder distension on dose distribution of intracavitary brachytherapy for cervical cancer: tree-dimentional computed tomography plan evaluation. Int J Rad Oncol Boil Phys. 2008;70(2):464-8.
29. Шакирова Э.Ж., Зидиханов Д.И. Спасительная (salvage) гистерэктомия после лучевой терапии рака шейки матки: обзор литературы. Опухоли женской репродуктивной системы. 2021;17(3):121-7. DOI: 10.17650/1994-4098-2021-17-3-121-127
30. Hanna T, Delaney G, Barton M. The population benefit of radiotherapy for gynaecological cancer: Local control and survival estimates. Radiother Oncol. 2016;20(3):370-7. DOI: 10.1016/j.radonc.2016.04.008
31. Delaney G, Jacob S, Barton M. Estimation of an optimal radiotherapy utilization rate for gynecologic carcinoma: part I—malignancies of the cervix, ovary, vagina and vulva. Cancer. 2004;101(4):671-81. DOI: 10.1002/cncr.20444. PMID: 15305396
32. Семьдесят третья сессия Всемирной ассамблеи здравоохранения. WHA 73.2. Пункт 11.4 повестки дня 3 августа 2020 г. Глобальная стратегия по ускорению элиминации рака шейки матки как проблемы общественного здравоохранения и установленные в ней цели и задачи на период 2020–2030 гг. URL: (Дата обращения 09.02.2022). WHA 73.2. Agenda item 11.4 August 3, 2020 Global Strategy to Accelerate the Elimination of Cervical Cancer as a Public Health Problem and its goals and targets for the period 2020–2030. URL: https://apps. who.int/gb/ebwha/pdf_files/WHA73/A73_R2-ru.pdf (Accessed 09. 02.2022) (in Russian).
33. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies. Results of the national practice in cancer of the cervix. Cancer. 1983;51(5):959-67. DOI: 10.1002/1097-0142(19830301)51:5<959::aid-cncr2820510533>3.0.co;2-k
34. Rodríguez-López JL, Ling DC, Keller A et al. Ureteral stenosis after 3D MRI-based brachytherapy for cervical cancer – Have we identified all the risk factors? Radiother Oncol. 2021;155:86-92. DOI: 10.1016/j.radonc.2020.10.010
35. Chopra S, Mangaj A, Sharma A et al. Management of oligo-metastatic and oligo-recurrent cervical cancer: A pattern of care survey within the EMBRACE research network. Radiother Oncol. 2021;155:151-9. DOI: 10.1016/j.radonc.2020.10.037
36. Tewari KS, Sill MW, Penson RT et al. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017;390(10103):1654-63. DOI: 10.1016/S0140-6736(17)31607-0
37. Jeon W, Koh HK, Kim HJ et al. Salvage radiotherapy for lymph node recurrence after radical surgery in cervical cancer. J Gynecol Oncol. 2012;23(3):168-74. DOI: 10.3802/jgo.2012.23.3.168
38. Ning MS, Ahobila V, Jhingran A et al. Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. Gynecol Oncol. 2018;148(1):132-8. DOI: 10.1016/j.ygyno.2017.10.017
39. Максимов С.Я., Гусейнов К.Д. Комбинированное лечение рака шейки матки. Практическая онкология. 2002;3(3):200-10. Maksimov S.Ya., Huseynov K.D. Combined treatment of cervical cancer. Practical oncology. 2002;3(3):200-10 (in Russian).
40. Ferreira P, Braga-Filho A, Barletta A, Ilha L. Radiation therapy alone in stage III-B cancer of the uterine cervix—a 17-year old experience in southern Brazil. Int J Radiat Oncol Biol Phys. 1999;45(2):441-6. DOI: 10.1016/s0360-3016(99)00178-9
41. Yahya S, Bhatt L, King M et al. Survival and Toxicity Following Chemoradiation for Carcinoma of the Cervix – Impact of Multiple-phase Treatment and Shielding. Anticancer Res. 2015;35(10):5567-74. PMID: 26408727.
42. Dimopoulos JC, Lang S, Kirisits C et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):56-63. DOI: 10.1016/j.ijrobp.2008.10.033
43. Pötter R, Dimopoulos J, Georg P et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiotherapy and Oncology. 2007;83(2):148-55. DOI: 10.1016/j.radonc.2007.04.012
44. Dimopoulos JC, Pötter R, Lang S et al. Dose-effect relationship for local control of cervical cancer by magnetic resonance image-guided brachytherapy. Radiother Oncol. 2009;93(2):311-5. DOI: 10.1016/j.radonc. 2009.07.001
45. Reijtenbagh D, Godart J, Penninkhof J et al. Nine years of plan of the day for cervical cancer: Plan library remains effective compared to fully online-adaptive techniques. Radiother Oncol. 2023;190:110009. DOI: 10.1016/j.radonc.2023.110009
46. Shelley CE, Bolt MA, Hollingdale R et al. Implementing cone-beam computed tomography-guided online adaptive radiotherapy in cervical cancer. Clin Transl Radiat Oncol. 2023;40:100596. DOI: 10.1016/j.ctro.2023.100596
47. Muramoto Y, Murakami N, Karino T et al. MucoUp® as a spacer in brachytherapy for uterine cervical cancer: A first-in-human experience. Clin Transl Radiat Oncol. 2023;42:100659. DOI: 10.1016/j.ctro.2023.100659
48. Duranson A, Thevenet V, Guyon F et al. Pelvic insufficiency fractures after intensity modulated radiation therapy combined with chemotherapy for cervix carcinoma: Incidence and impact of bone mineral density. Clin Transl Radiat Oncol. 2023;41:100650. DOI: 10.1016/j.ctro.2023.100650
49. Massock W, Kim Y, Dresner MA et al. MRI-Guided High-Dose-Rate Gynecologic Brachytherapy Using an MR-Linac as an MR Simulator: A Single Institutional Experience. Pract Radiat Oncol. 2023:S1879-8500(23)00230-8. DOI: 10.1016/j.prro.2023.08.003
50. Li H, Wang S, Liu Y et al. Prophylactic extended-field irradiation for locally advanced cervical cancer. Gynecol Oncol. 2022;166(3):606-13. DOI: 10.1016/j.ygyno.2022.07.009
51. Olawaiye AB, Baker TP, Washington MK, Mutch DG. The new (Version 9) American Joint Committee on Cancer tumor, node, metastasis staging for cervical cancer. CA Cancer J Clin. 2021;71(4):287-98. DOI: 10.3322/caac.21663
For citation:Stolbovoy A.V., Islim N., Loiko I.E., Zvereva D.P., Sobina S.S. Issues in the treatment of cervix uteri. Clinical analysis in general medicine. 2024; 5 (7): 59–68. (In Russ.). DOI: 10.47407/kr2024.5.7.00448
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
